The primary focus of Kalin’s laboratory is to develop the new therapies for patients with cancer and with interstitial lung diseases. We are actively involved in drug development by screening for new therapeutic compounds to inhibit carcinogenesis and to alleviate the long-term complication after non-resolved lung injury caused by radiation treatment, chemotherapy, or viral infections. Using clinical tissue samples, human ex vivo models and animal models, we aim to understand the complex signaling networks that regulate disease progression with the goal to target the abnormal signaling to improve patients’ survival and disease outcomes.